Progress on AstraZenecaOf (NYSE: AZN) The coronovirus vaccine candidate breathed a sigh of relief this week after an adverse health event began enrollment at test sites around the world. Despite the setback, Wednesday afternoon, CEO Pascal Soriott told analysts that he still expected interim results from several Phase 3 studies of the candidate before the end of the year if those tests were allowed to continue soon.
On Tuesday, AstraZeneca released statements describing a partial hold on Phase 3 trials of AZD1222. The company is one of the frontrunners in the race to develop vaccines, which teaches our immune system to recognize and attack SARS-CoV-2, which causes the coronavi virus, which causes COVID-19 Is, before it gains a foothold in the body.
Vaccination is widely used in the event that any adverse event severely requires hospitalization of a participant in their clinical trials that may force researchers to stop injecting new patients is. Given the size of those late-stage tests, such incidents are not uncommon. Panels of independent data and safety monitors review them and usually determine them to be unrelated to the vaccine being studied, after which most trials continue without nuisance.
However, the medical community at AZD1222 is extra cautious because it uses a viral vector to do its job. Viral vectors cannot infect, but some of them are associated with severe immune system responses in clinical-stage testing.
In a statement released on Thursday, AstraZeneca confirmed that the AZD1222 study had a brief halt in July, while a safety review took place. The volunteer whose symptoms were triggered revealed multiple sclerosis, a progressive neurological disorder, in which patients’ immune systems attack their own nervous system.
We still do not know the diagnosis of the latest patient to stop testing for AZD1222, and AstraZeneca has not provided a timeline.